Experienced in Congenital Hyperinsulinism

Bart I. Keymeulen

Universitair Ziekenhuis Brussel
Brussels, BRU, BE 
Experienced in Congenital Hyperinsulinism
Universitair Ziekenhuis Brussel
Brussels, BRU, BE 
OverviewLocationsClinical Research

Overview

Bart Keymeulen practices in Brussels, Belgium. Mr. Keymeulen is rated as an Experienced expert by MediFind in the treatment of Congenital Hyperinsulinism. His top areas of expertise are Type 1 Diabetes (T1D), Low Blood Sugar, Agenesis of the Dorsal Pancreas, Heterotaxy Syndrome, and Islet Cell Transplantation.

His clinical research consists of co-authoring 83 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Congenital Hyperinsulinism.

Gender
Male

Locations

Universitair Ziekenhuis Brussel
Brussels, BRU, Belgium

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

MELD-ATG: Phase II, Dose Ranging, Efficacy Study of Anti-thymocyte Globulin (ATG) Within 6 Weeks of Diagnosis of Type 1 Diabetes (T1D)
MELD-ATG: Phase II, Dose Ranging, Efficacy Study of Anti-thymocyte Globulin (ATG) Within 6 Weeks of Diagnosis of Type 1 Diabetes (T1D)
Enrollment Status: Completed
Publish Date: January 10, 2025
Intervention Type: Drug
Study Drug: Anti-Human Thymocyte Immunoglobulin, Rabbit
Study Phase: Phase 2
A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of Verapamil SR on Preservation of Beta-cell Function (Ver-A-T1D)
A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of Verapamil SR on Preservation of Beta-cell Function (Ver-A-T1D)
Enrollment Status: Active_not_recruiting
Publish Date: October 30, 2024
Intervention Type: Drug
Study Drug: Verapamil SR
Study Phase: Phase 2
A Phase 2, Multicentre, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of 400 mg Twice a Day Oral Ladarixin in Patients With New-onset Type 1 Diabetes
A Phase 2, Multicentre, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of 400 mg Twice a Day Oral Ladarixin in Patients With New-onset Type 1 Diabetes
Enrollment Status: Completed
Publish Date: April 19, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Prospective, Multi-center, Phase 1b/2a Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Association With Teplizumab in Patients With Clinical Recent-onset Type 1 Diabetes Mellitus (T1D)
A Prospective, Multi-center, Phase 1b/2a Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Association With Teplizumab in Patients With Clinical Recent-onset Type 1 Diabetes Mellitus (T1D)
Enrollment Status: Completed
Publish Date: February 01, 2023
Intervention Type: Biological, Drug
Study Drugs: AG019 - Low Dose, Teplizumab, AG019 - High Dose, AG019 - Low or High Dose
Study Phase: Phase 1/Phase 2
View 3 Less Clinical Trials

83 Total Publications

One-year real-world benefits of Tandem Control-IQ technology on glucose management and person-reported outcomes in adults with type 1 diabetes: a prospective observational cohort study.
One-year real-world benefits of Tandem Control-IQ technology on glucose management and person-reported outcomes in adults with type 1 diabetes: a prospective observational cohort study.
Journal: Diabetologia
Published: December 02, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Keymeulen's expertise for a condition
ConditionClose
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile